Related Experiment Video
Updated: Apr 21, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Clearing hurdles in anticoagulation therapy: drug trends in cardiology
Insights
Initiating novel oral anticoagulants (NOACs) involves challenges in dosing for venous thromboembolism (VTE) or stroke prevention, practical use, and managing bleeding risks.
Area of Science:
- Pharmacology
- Cardiology
- Hematology
Background:
- Novel oral anticoagulants (NOACs) offer alternatives to traditional therapies for thromboembolic disorders.
- Effective initiation of NOACs requires understanding specific clinical contexts.
Discussion:
- Key challenges in NOAC therapy include variable dosing for venous thromboembolism (VTE) treatment versus stroke prevention.
- Practical administration and patient adherence are crucial for successful NOAC implementation.
- Managing potential bleeding events is a significant concern in NOAC therapy.
Key Insights:
- Dosing strategies for NOACs must be tailored to the indication (VTE treatment or stroke prevention).
- Simplifying the practical application of NOACs can improve clinical uptake.
- Proactive management of bleeding risks is essential for patient safety with NOACs.
Outlook:
- Further research may refine NOAC dosing and management protocols.
- Educational initiatives are needed to address the practical hurdles of NOAC initiation.
- Optimizing NOAC use will enhance the treatment of thrombotic conditions.
Abstract:
The hurdles that need to be cleared when initiating therapy with the novel anticoagulants (NOACs) are the following, says Prof Sylvia Haas: 'The different dosing regimens, depending on whether these agents are being used for venous thromboembolism (VTE) treatment or stroke prevention. The practical usage of them. The management of bleeding associated with their use.' She was speaking at a meeting held in Johannesburg in late July as a guest of Bayer Healthcare.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease V: Interprofessional Care

